BioMedSA’s Board of Directors approved 2 new memberships in April, 2022: BellaMia Technologies, and NanoHarmonics.
BellaMia Technologies is developing a laser-based medical device to perform non-invasive facial rejuvenation for men and women. The device will be the first non-contact robotic laser using artificial intelligence to allow physicians to choose treatment parameters effortlessly with the touch of a button. The advanced sensor technology and 3-D imaging is intended to create precision custom treatments for patients with less recovery time.
NanoHarmonics is creating diagnostic biomarker tests using their patented Quantum Dot technology, Abacus™. They have conducted clinical trials on their first applications: sepsis, COVID-19 antigens and COVID-19 neutralizing antibodies. They have recently partnered with Avagen Pharma in order to work towards their goal of improving pharmaceutical and diagnostics within the healthcare industry.